TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic in acute ischemic stroke and TTP

TargED United Kingdom United States of America Netherlands

TGD001 is being developed to offer patients with clotting disorders a faster, safer and more effective treatment than today's standard of care – saving lives and reducing disabilityFollowing the Phase 1 safety study, TargED intends to further develop TGD001 in patients with AIS and iTTP (a rare micro-thrombotic disorder) in the second half of 2025View original content:https://www.prnewswire.co.uk/news-releases/targed-biopharmaceuticals-doses-first-participant-in-phase-1-clinical-trial-of-tgd001-a-groundbreaking-thrombolytic-in-acute-ischemic-stroke-ais-and-ttp-302335213.html